Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-11579
Eur J Pharmacol 2000 Jan 17;3873:R19-21. doi: 10.1016/s0014-2999(99)00834-1.
Show Gene links Show Anatomy links

The novel pyridoxal-5'-phosphate derivative PPNDS potently antagonizes activation of P2X(1) receptors.

Lambrecht G , Rettinger J , Bäumert HG , Czeche S , Damer S , Ganso M , Hildebrandt C , Niebel B , Spatz-Kümbel G , Schmalzing G , Mutschler E .


???displayArticle.abstract???
Pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonat e) (PPNDS) potently antagonized P2X(1) receptor-mediated responses in rat vas deferens (pK(B)=7.43) and Xenopus laevis oocytes (pIC(50)=7. 84). It showed lower (up to 20,000-fold) inhibitory potency on ecto-nucleotidase in Xenopus oocytes and on P2Y(1) receptors in guinea-pig ileum (pA(2)=6.13). PPNDS did not interact with alpha(1A)-adrenoceptors, adenosine A(1) and A(2B), histamine H(1) and muscarinic M(3) receptors. Thus, PPNDS is a novel, specific P2 receptor antagonist and represents the pyridoxal-5'-phosphate derivative with the highest potency at P2X(1) receptors.

???displayArticle.pubmedLink??? 10650184
???displayArticle.link??? Eur J Pharmacol